KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Equity Average (2016 - 2026)

Pacira BioSciences has reported Equity Average over the past 16 years, most recently at $673.5 million for Q1 2026.

  • For Q1 2026, Equity Average fell 14.58% year-over-year to $673.5 million; the TTM value through Mar 2026 reached $673.5 million, down 14.58%, while the annual FY2025 figure was $735.7 million, 10.74% down from the prior year.
  • Equity Average for Q1 2026 was $673.5 million at Pacira BioSciences, down from $710.2 million in the prior quarter.
  • Over five years, Equity Average peaked at $885.7 million in Q2 2024 and troughed at $673.5 million in Q1 2026.
  • A 5-year average of $779.8 million and a median of $772.6 million in 2022 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: rose 14.21% in 2024 and later fell 14.58% in 2026.
  • Year by year, Equity Average stood at $772.6 million in 2022, then grew by 10.13% to $850.8 million in 2023, then dropped by 10.21% to $764.0 million in 2024, then fell by 7.04% to $710.2 million in 2025, then decreased by 5.16% to $673.5 million in 2026.
  • Business Quant data shows Equity Average for PCRX at $673.5 million in Q1 2026, $710.2 million in Q4 2025, and $742.5 million in Q3 2025.